EligibleTrials

Clinical trials recruiting for Advanced Prostate Cancer

13
Recruiting trials
8
US states with sites
14
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 7Phase 2 3Not applicable 5

Drugs and treatments being studied

InterventionTrials
HRS-50412
18F-fluciclovine1
Abiraterone acetate1
Abiraterone acetate tablets1
Docetaxel injection1
Enzalutamide1
Enzalutamide Soft Capsules1
GDC-12611
HS-10502 + Bevacizumab1
HS-10502 + HS-200891
HS-10502 + HS-200931
HS-10502 + NHA1

Where trials are recruiting (top US states)

StateRecruiting trials
Arizona2
Texas2
Connecticut1
Florida1
Illinois1
Massachusetts1
North Carolina1
Tennessee1

Top cities

Scottsdale, Arizona 2Boston, Massachusetts 1Chicago, Illinois 1Durham, North Carolina 1Houston, Texas 1Nashville, Tennessee 1Nashville, Texas 1New Haven, Connecticut 1Orlando, Florida 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Advanced Prostate Cancer often also study these conditions. Each links to its own recruiting-trial list.

Prostate cancer 1234Metastatic Prostate Cancer 45Breast cancer 2239Advanced Breast Cancer 61TNBC 5Prostate Cancer Recurrent 11Prostate Cancer Metastatic Disease 9Multiple myeloma 16Lymphoma 29Lung cancer 2180

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Advanced Prostate Cancer trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.